The BluePrint Molecular Subtyping Profile combined with the patient's MammaPrint test result, provides a greater level of clinical information to assist in therapeutic decision-making. BluePrint is an 80-gene expression signature which classifies breast cancer into Basal-type, Luminal-type and ERBB2-type cancers. An increasing body of evidence in the medical community suggests that breast cancer patients within these molecular subgroups have different prognoses with varied responses to specific ... Read more
The supplier does not provide quotations for this product through SelectScience. Browse these related products instead
Related Products
BluePrint
The supplier does not provide quotations for this particular product through SelectScience. You can search for similar products in our product directory.
The BluePrint Molecular Subtyping Profile combined with the patient's MammaPrint test result, provides a greater level of clinical information to assist in therapeutic decision-making.
BluePrint is an 80-gene expression signature which classifies breast cancer into Basal-type, Luminal-type and ERBB2-type cancers.
An increasing body of evidence in the medical community suggests that breast cancer patients within these molecular subgroups have different prognoses with varied responses to specific therapies.
BluePrint is an 80-gene expression signature which classifies breast cancer into Basal-type, Luminal-type and ERBB2-type cancers.
An increasing body of evidence in the medical community suggests that breast cancer patients within these molecular subgroups have different prognoses with varied responses to specific therapies.
Product Overview
